ANTIPSYCHOTICS - HISTORY OF DEVELOPMENT AND FIELD OF
... long-time work in the treatment of patients with schizophrenia, we focused on studying efficacy and tolerability of antipsychotic therapy, particularly of the SGA (Jašović-Gašić & Marić 2004). Numerous studies we conducted have confirmed the efficacy of SGA in the treatment of positive and negative ...
... long-time work in the treatment of patients with schizophrenia, we focused on studying efficacy and tolerability of antipsychotic therapy, particularly of the SGA (Jašović-Gašić & Marić 2004). Numerous studies we conducted have confirmed the efficacy of SGA in the treatment of positive and negative ...
2013 Newsletter
... For the past few decades, health officials have been reporting increases in the incidence of autoimmune diseases such as multiple sclerosis. Now researchers at Yale Medical School, Harvard Medical School and the Broad Institute have identified a prime suspect in the mystery – dietary salt. In the Ma ...
... For the past few decades, health officials have been reporting increases in the incidence of autoimmune diseases such as multiple sclerosis. Now researchers at Yale Medical School, Harvard Medical School and the Broad Institute have identified a prime suspect in the mystery – dietary salt. In the Ma ...
DEPARTMENT OF MEDICINE 41 ANNUAL RESEARCH DAY DATE: THURSDAY, 09 OCTOBER 2014
... Effectiveness of task-sharing between doctors and nurses on outcomes of noncommunicable chronic disease management in primary care in South Africa: pragmatic ...
... Effectiveness of task-sharing between doctors and nurses on outcomes of noncommunicable chronic disease management in primary care in South Africa: pragmatic ...
Osteoarthritis - WHO archives
... generally reserved for failed medical management where functional disability affects a patient’s quality of life. Pharmacological management includes control of pain and improvement in function and quality of life while limiting drug toxicity. Experts in this field suggest that appropriate therapy f ...
... generally reserved for failed medical management where functional disability affects a patient’s quality of life. Pharmacological management includes control of pain and improvement in function and quality of life while limiting drug toxicity. Experts in this field suggest that appropriate therapy f ...
Desferal - Novartis Pharmaceuticals Corporation
... sensorineural hearing loss. In most cases, both ocular and auditory disturbances were reversible upon immediate cessation of treatment (see PRECAUTIONS/Information for Patients and ADVERSE REACTIONS/Special Senses). Visual acuity tests, slit-lamp examinations, funduscopy and audiometry are recommend ...
... sensorineural hearing loss. In most cases, both ocular and auditory disturbances were reversible upon immediate cessation of treatment (see PRECAUTIONS/Information for Patients and ADVERSE REACTIONS/Special Senses). Visual acuity tests, slit-lamp examinations, funduscopy and audiometry are recommend ...
GENTAMICIN OPHTHALMIC Garamycin and Sandoz
... Garamycin and Sandoz gentamicin ophthalmic products have been discontinued.1,2 Although several other generic brands have been approved by Health Canada, none are currently being marketed in Canada.3 Handling the shortage: 1. Is antibiotic therapy necessary? ...
... Garamycin and Sandoz gentamicin ophthalmic products have been discontinued.1,2 Although several other generic brands have been approved by Health Canada, none are currently being marketed in Canada.3 Handling the shortage: 1. Is antibiotic therapy necessary? ...
Irritable bowel syndrome in adults (19-09-11)
... • Consider TCAs for their analgesic effect if first-line treatments do not help – Start at a low dose (5-10mg amitriptyline) taken once at night and review regularly – Dose may be increased (should not usually exceed 30mg) • Consider SSRIs only if TCAs are ineffective • Take into account possible si ...
... • Consider TCAs for their analgesic effect if first-line treatments do not help – Start at a low dose (5-10mg amitriptyline) taken once at night and review regularly – Dose may be increased (should not usually exceed 30mg) • Consider SSRIs only if TCAs are ineffective • Take into account possible si ...
Dehydration: New Approaches to an Age
... with most other conditions and comorbidities can use home care or over-the-counter treatments unless severe dehydration occurs, a bacterial pathogen may be the cause, or acid–base imbalance develops. 6. Oral rehydration salts were originally developed for treating which of the following conditions? ...
... with most other conditions and comorbidities can use home care or over-the-counter treatments unless severe dehydration occurs, a bacterial pathogen may be the cause, or acid–base imbalance develops. 6. Oral rehydration salts were originally developed for treating which of the following conditions? ...
Safe and Effective Treatment of Aggressive Non
... McCloskey and associates reported successful treatment results using bendamustine plus rituximab in 2 patients with aggressive B-cell NHL and severe liver impairment.10 The total serum bilirubin levels in both patients were more than 10 times the upper limit of normal (ULN; 24.3 mg/dL in case 1 and ...
... McCloskey and associates reported successful treatment results using bendamustine plus rituximab in 2 patients with aggressive B-cell NHL and severe liver impairment.10 The total serum bilirubin levels in both patients were more than 10 times the upper limit of normal (ULN; 24.3 mg/dL in case 1 and ...
Laser Hair Removal
... treatment. Fountain of Youth is not responsible for any adverse side effects that result from undocumented changes in the client’s medical history and/or medication regimen. Post Treatment Guidelines After the treatment, you can expect the treatment area to be pink and slightly swollen. Side effects ...
... treatment. Fountain of Youth is not responsible for any adverse side effects that result from undocumented changes in the client’s medical history and/or medication regimen. Post Treatment Guidelines After the treatment, you can expect the treatment area to be pink and slightly swollen. Side effects ...
Risk Factor - Public Health Wales
... • Local Risk assessment to determine need for Patient Notification Exercise (PNE) • Advice on risk patient to patient transmission not strictly with UKAP remit ...
... • Local Risk assessment to determine need for Patient Notification Exercise (PNE) • Advice on risk patient to patient transmission not strictly with UKAP remit ...
Diverticular disease of the colon
... minor patchy inflammation of the bowel wall in segments of bowel affected but severe diverticulosis. What are the symptoms patients may get in uncomplicated diverticulosis (not diverticulitis)? Because of the changes in the bowel mentioned above, patients may have noticed gradual changes in how thei ...
... minor patchy inflammation of the bowel wall in segments of bowel affected but severe diverticulosis. What are the symptoms patients may get in uncomplicated diverticulosis (not diverticulitis)? Because of the changes in the bowel mentioned above, patients may have noticed gradual changes in how thei ...
J.P. Morgan Healthcare Conference 2017
... manufacture or otherwise commercialize our product candidates, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, any royalty payments, and our ability to obtain and maintain intellectual property protection for our product can ...
... manufacture or otherwise commercialize our product candidates, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, any royalty payments, and our ability to obtain and maintain intellectual property protection for our product can ...
LABORATORY SYNDROMES IN Acute hepatitis
... Interferon alfacon-1 (Infergen). This agent is referred to as a consensus interferon (CIFN) because it was genetically developed using the most commonly occurring amino acid sequences from each of the natural type 1 alpha interferons. It is usually given three times a week when used as initial treat ...
... Interferon alfacon-1 (Infergen). This agent is referred to as a consensus interferon (CIFN) because it was genetically developed using the most commonly occurring amino acid sequences from each of the natural type 1 alpha interferons. It is usually given three times a week when used as initial treat ...
Gastroesophageal Reflux Disease (GERD)
... GERD is a chronic disease that affects patients across all age groups with equal distribution between men and women. The prevalence of GERD appears to be greater in the Western population with patients presenting with more clinically important disease and complications than in Eastern countries (esp ...
... GERD is a chronic disease that affects patients across all age groups with equal distribution between men and women. The prevalence of GERD appears to be greater in the Western population with patients presenting with more clinically important disease and complications than in Eastern countries (esp ...
Positive Aspects of Side Effects: Part II Treating Stress
... automatically adjusts to changes in the demands that are placed on the body, as does our heart rate, blood pressure, and other physiological parameters. If the stress encountered is too severe or lasts too long, it may exceed the body’s ability to maintain homeostasis. In such cases, the individual ...
... automatically adjusts to changes in the demands that are placed on the body, as does our heart rate, blood pressure, and other physiological parameters. If the stress encountered is too severe or lasts too long, it may exceed the body’s ability to maintain homeostasis. In such cases, the individual ...
Poor Performance Status is not Always a Contraindication to
... benefit from therapy, either chemotherapy (single agent or combination) or oral TKI, with amelioration of symptoms, improvement in their quality of life and possibly prolonged survival. It may be worthwhile to consider performing a prospective clinical trial on this subset of PS 3 patients to best d ...
... benefit from therapy, either chemotherapy (single agent or combination) or oral TKI, with amelioration of symptoms, improvement in their quality of life and possibly prolonged survival. It may be worthwhile to consider performing a prospective clinical trial on this subset of PS 3 patients to best d ...
Comparison of short-course multidrug treatment with standard
... For the per-protocol population, after exclusion of the nine patients withdrawn because of serious and non-serious adverse events (regarded as failure in the ITT analyses), the cure rate was 98∙6% for the standard treatment. Nephrotoxicity is a well known side effect of amphotericin B treatment.There ...
... For the per-protocol population, after exclusion of the nine patients withdrawn because of serious and non-serious adverse events (regarded as failure in the ITT analyses), the cure rate was 98∙6% for the standard treatment. Nephrotoxicity is a well known side effect of amphotericin B treatment.There ...
3 Treatment of Dry Mouth
... is a complex biofilm of microbes that adheres to the surfaces of teeth and provides a reservoir for oral microbial pathogens (Paster, 2001 #49). Streptococci account for approximately 20% of the total number of oral bacteria, and they are predominantly the first colonizers of freshly cleaned enamel ...
... is a complex biofilm of microbes that adheres to the surfaces of teeth and provides a reservoir for oral microbial pathogens (Paster, 2001 #49). Streptococci account for approximately 20% of the total number of oral bacteria, and they are predominantly the first colonizers of freshly cleaned enamel ...
Cyclic Vomiting Syndrome in Adults
... Treatment Treatment of cyclic vomiting syndrome remains largely empiric because of its obscure pathogenesis and the lack of controlled therapeutic trials. In general, the treatment approach to a patient with CVS should include consideration of lifestyle changes including avoidance of potential trigg ...
... Treatment Treatment of cyclic vomiting syndrome remains largely empiric because of its obscure pathogenesis and the lack of controlled therapeutic trials. In general, the treatment approach to a patient with CVS should include consideration of lifestyle changes including avoidance of potential trigg ...
Gastroesophageal Reflux Disease (GERD)
... It has also been estimated that 7% of the U.S. population have complicated GERD associated with erosive esophagitis. Up to 75% of patients who undergo endoscopic procedures due to symptoms associated with GERD have normal esophageal findings. These patients are identified as having functional heartb ...
... It has also been estimated that 7% of the U.S. population have complicated GERD associated with erosive esophagitis. Up to 75% of patients who undergo endoscopic procedures due to symptoms associated with GERD have normal esophageal findings. These patients are identified as having functional heartb ...
Immune Reconstitution Inflammatory Syndrome (IRIS) Demetre C
... HAART-induced immune reconstitution. Cervical and mediastinal lymphadenopathy and cutaneous lesions are alternate ways patients may present. Generalizations are difficult to make since experience with post-HAART cryptococcal IRIS is very limited. Antifungals are the mainstay of therapy. Anti-inflamm ...
... HAART-induced immune reconstitution. Cervical and mediastinal lymphadenopathy and cutaneous lesions are alternate ways patients may present. Generalizations are difficult to make since experience with post-HAART cryptococcal IRIS is very limited. Antifungals are the mainstay of therapy. Anti-inflamm ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.